Analyst Reaffirms Buy Rating for Zevra Therapeutics with 15 Price Target
On March 5, 2024, analyst Oren Livnat from HC Wainwright & Co. reiterated a bullish stance on Zevra Therapeutics (NASDAQ: ...
© 2024 Stocks Today
Tag: ZVRA
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools